GSK PLC ADR
GSK: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$78.00 | Cktw | Bnxhnwdj |
Despite Recent Litigation Headwinds on Zantac, GSK Remains Well Positioned for Earnings Growth
Business Strategy and Outlook
As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion.